



(12) Translation of
European patent specification

(11) NO/EP 2389187 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/192 (2006.01)
A61K 31/19 (2006.01)
A61K 31/196 (2006.01)
A61K 31/22 (2006.01)
A61K 31/235 (2006.01)
A61K 31/245 (2006.01)
A61K 45/06 (2006.01)
A61P 25/00 (2006.01)
A61P 25/18 (2006.01)
A61P 25/22 (2006.01)
A61P 25/24 (2006.01)
A61P 25/26 (2006.01)
A61P 25/28 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.04.03
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.11.16
(86)	European Application Nr.	10733788.3
(86)	European Filing Date	2010.01.19
(87)	The European Application's Publication Date	2011.11.30
(30)	Priority	2009.01.20, US, 145931 P
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
(73)	Proprietor	Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson Street, Torrance, CA 90502-2064, US-USA
(72)	Inventor	TSAl, Guochuan, Emil, Pasadena, California, US-USA
(74)	Agent or Attorney	Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54)	Title	SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL
(56)	References Cited:	WO-A1-2007/093829 DE-A1- 4 340 273 US-A- 3 498 989 US-A- 3 870 715 US-A- 4 041 174 US-A- 4 956 363 US-A- 5 453 425 US-A- 5 658 900 US-A1- 2001 044 446 US-A1- 2003 185 754 US-A1- 2004 138 197 US-A1- 2004 156 872 US-A1- 2005 004 104

US-A1- 2005 250 738
 US-A1- 2005 267 176
 US-A1- 2005 272 721
 US-A1- 2008 045 512
 US-B1- 6 569 848
 US-B1- 6 746 678
 US-B2- 7 094 930
 US-B2- 7 166 725

ADAGE ET AL: "In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, AMSTERDAM, NL, vol. 18, no. 3, 18 January 2008 (2008-01-18), pages 200-214, XP022426688, ISSN: 0924-977X, DOI: 10.1016/J.EURONEURO.2007.06.006

DATABASE EMBASE [Online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1953, MOTTA E: "Use of PABA in 3 groups of schizophrenics (agitated, apathic and confused)", XP002715127, Database accession no. EMB-0007179114 & MOTTA E: "Use of PABA in 3 groups of schizophrenics (agitated, apathic and confused)", RASSEGNA DI STUDI PSICHIATRICI 1953, vol. 42, no. 4, 1953, pages 731-740, ISSN: 0033-9636

WENJUAN ZHAO ET AL: "Inhibition of d-Amino-Acid Oxidase Activity Induces Pain Relief in Mice", CELLULAR AND MOLECULAR NEUROBIOLOGY, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 28, no. 4, 15 September 2007 (2007-09-15), pages 581-591, XP019787867, ISSN: 1573-6830

SPAREY T ET AL: "The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 11, June 2008 (2008-06), pages 3386-3391, XP022711233, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2008.04.020 [retrieved on 2008-04-13]

SMITH S M ET AL: "The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 328, no. 3, March 2009 (2009-03), pages 921-930, XP009126779, ISSN: 0022-3565, DOI: 10.1124/JPET.108.147884

FERRARIS DANNA ET AL: "D-Amino Acid Oxidase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 12, June 2008 (2008-06), pages 3357-3359, XP055204564, ISSN: 0022-2623, DOI: 10.1021/jm800200u

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

5 **1.** Sammensetning for anvendelse i en fremgangsmåte for å mildne ett eller flere symptomer ved schizofreni, **karakterisert ved at** sammensetningen omfatter effektive mengder av en første og en andre aktiv forbindelse, hvori den første forbindelsen er et antipsykotisk legemiddel, og den andre forbindelsen er benzosyre eller et benzosyresalt, hvori benzosyresaltet er valgt fra gruppen bestående av natriumbenzoat, kaliumbenzoat, kalsiumbenzoat og litiumbenzoat, og hvori mengden av benzosyre eller benzosyresalt er tilstrekkelig til å øke
10 effektiviteten til det antipsykotiske legemiddelet og spenner fra ca. 5 mg til ca. 500 g.

15 **2.** Sammensetningen for anvendelse ifølge krav 1, hvori det antipsykotiske legemiddelet er valgt fra gruppen bestående av butyrofenon, fenotiazin, flufenazin, perfenazin, proklorperazin, tioridazin, trifluoperazin, mesoridazin, promazin, triflupromazin, levomepromazin, prometazin, tioxanten, klorprotixen, flupentixol, tiotixen, zuklopentiksol, klozapin, olanzapin, risperidon, quetiapin, ziprasidon, amisulprid, asenapin, paliperidon, aripiprazol, en partiell dopaminagonist (BIFEPRUNOX®, NORCLOZAPINE ®(ACP-104)), lamotrigin,
20 memantin, tetrabenazin, cannabidiol, LY2140023, Droperidol, Pimozid, Butaperazin, Carphenazin, Remoxiprid, Piperacetazin, Sulpirid, acamprosate og tetrabenazin (XENAZINE ®, NITOMAN®).

25 **3.** Benzosyre eller et benzosyresalt for anvendelse i en fremgangsmåte for å mildne ett eller flere symptomer ved schizofreni, hvori benzosyresaltet er valgt fra gruppen bestående av natriumbenzoat, kaliumbenzoat, kalsiumbenzoat og litiumbenzoat, og hvori mengden av benzosyre eller benzosyresalt er tilstrekkelig til å mildne ett eller flere av symptomene og spenner fra ca. 5 mg til ca. 500 g.